首页> 美国卫生研究院文献>Materials >Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release
【2h】

Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release

机译:基于滑石粉和壳聚糖的混合系统可控药物释放

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Inorganic matrices and biopolymers have been widely used in pharmaceutical fields. They show properties such as biocompatibility, incorporation capacity, and controlled drug release, which can become more attractive if they are combined to form hybrid materials. This work proposes the synthesis of new drug delivery systems (DDS) based on magnesium phyllosilicate (Talc) obtained by the sol–gel route method, the biopolymer chitosan (Ch), and the inorganic-organic hybrid formed between this matrix (Talc + Ch), obtained using glutaraldehyde as a crosslink agent, and to study their incorporation/release capacity of amiloride as a model drug. The systems were characterized by X-ray diffraction (XRD), Therma analysis TG/DTG, and Fourier-transform infrared spectroscopy (FTIR) that supported the DDS’s formation. The hybrid showed a better drug incorporation capacity compared to the precursors, with a loading of 55.74, 49.53, and 4.71 mg g for Talc + Ch, Talc, and Ch, respectively. The release assays were performed on a Hanson Research SR-8 Plus dissolver using apparatus I (basket), set to guarantee the sink conditions. The in vitro release tests showed a prolongation of the release rates of this drug for at least 4 h. This result proposes that the systems implies the slow and gradual release of the active substance, favoring the maintenance of the plasma concentration within a therapeutic window.
机译:无机基质和生物聚合物已广泛用于制药领域。它们显示出诸如生物相容性,掺入能力和受控药物释放等特性,如果将它们结合形成杂化材料,这些特性将变得更具吸引力。这项工作提出了一种新的药物递送系统(DDS)的合成方法,该方法基于通过溶胶-凝胶法获得的页硅酸镁(Talc),生物聚合物壳聚糖(Ch)以及在该基质之间形成的无机-有机杂化体(Talc + Ch ),使用戊二醛作为交联剂获得,并研究它们作为模型药物阿米洛利的掺入/释放能力。该系统的特征在于X射线衍射(XRD),热分析TG / DTG和支持DDS形成的傅立叶变换红外光谱(FTIR)。与前体相比,该杂化物显示出更好的药物掺入能力,滑石粉+ Ch,滑石粉和Ch的载量分别为55.74、49.53和4.71 mg g。释放测定是在Hanson Research SR-8 Plus溶解器上使用设备I(篮子)进行的,该设备设置为可确保水槽条件。体外释放试验表明该药物的释放速率至少延长了4小时。该结果表明,该系统暗示了活性物质的缓慢和逐渐释放,有利于维持治疗窗内的血浆浓度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号